These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 22476901)
1. The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression. Tu Z; Li H; Ma Y; Tang B; Tian J; Akers W; Achilefu S; Gu Y Mol Cell Biochem; 2012 Jul; 366(1-2):111-22. PubMed ID: 22476901 [TBL] [Abstract][Full Text] [Related]
2. Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation. Hoffman KL; Lerner SP; Smith CL Horm Cancer; 2013 Feb; 4(1):24-35. PubMed ID: 22965848 [TBL] [Abstract][Full Text] [Related]
4. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. Fan J; Yin WJ; Lu JS; Wang L; Wu J; Wu FY; Di GH; Shen ZZ; Shao ZM J Cancer Res Clin Oncol; 2008 Aug; 134(8):883-90. PubMed ID: 18264725 [TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Alao JP; Lam EW; Ali S; Buluwela L; Bordogna W; Lockey P; Varshochi R; Stavropoulou AV; Coombes RC; Vigushin DM Clin Cancer Res; 2004 Dec; 10(23):8094-104. PubMed ID: 15585645 [TBL] [Abstract][Full Text] [Related]
6. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer. Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091 [TBL] [Abstract][Full Text] [Related]
7. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells. Dardes RC; Schafer JM; Pearce ST; Osipo C; Chen B; Jordan VC Gynecol Oncol; 2002 Jun; 85(3):498-506. PubMed ID: 12051881 [TBL] [Abstract][Full Text] [Related]
8. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft. Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847 [TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of silver nanoparticles on proliferation of estrogen-dependent MCF-7/BUS human breast cancer cells induced by butyl paraben or di-n-butyl phthalate. Roszak J; Smok-Pieniążek A; Domeradzka-Gajda K; Grobelny J; Tomaszewska E; Ranoszek-Soliwoda K; Celichowski G; Stępnik M Toxicol Appl Pharmacol; 2017 Dec; 337():12-21. PubMed ID: 29074358 [TBL] [Abstract][Full Text] [Related]
10. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β. Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400 [TBL] [Abstract][Full Text] [Related]
11. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Jang ER; Lim SJ; Lee ES; Jeong G; Kim TY; Bang YJ; Lee JS Oncogene; 2004 Mar; 23(9):1724-36. PubMed ID: 14676837 [TBL] [Abstract][Full Text] [Related]
12. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Walton TJ; Li G; Seth R; McArdle SE; Bishop MC; Rees RC Prostate; 2008 Feb; 68(2):210-22. PubMed ID: 18092350 [TBL] [Abstract][Full Text] [Related]
13. Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: synthesis, structure-activity relationships and molecular modeling study for flexible estrogen receptor antagonists. Lloyd DG; Smith HM; O'Sullivan T; Knox AS; Zisterer DM; Meegan MJ Med Chem; 2006 Mar; 2(2):147-68. PubMed ID: 16787364 [TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor β potentiates the antiproliferative effect of raloxifene and affects the cell migration and invasion in HCT-116 colon cancer cells. Tu Z; Ma Y; Tian J; Li H; Akers W; Achilefu S; Gu Y J Cancer Res Clin Oncol; 2012 Jul; 138(7):1091-103. PubMed ID: 22398780 [TBL] [Abstract][Full Text] [Related]
15. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042 [TBL] [Abstract][Full Text] [Related]
16. Effect of Curcumin in Comparison with Trichostatin A on the Reactivation of Estrogen Receptor Alpha gene Expression, Cell Growth Inhibition and Apoptosis Induction in Hepatocellular Carcinoma Hepa 1-6 Cell lLine. Sanaei M; Kavoosi F; Arabloo M Asian Pac J Cancer Prev; 2020 Apr; 21(4):1045-1050. PubMed ID: 32334468 [TBL] [Abstract][Full Text] [Related]
17. Neuroprotective action of raloxifene against hypoxia-induced damage in mouse hippocampal cells depends on ERα but not ERβ or GPR30 signalling. Rzemieniec J; Litwa E; Wnuk A; Lason W; Gołas A; Krzeptowski W; Kajta M J Steroid Biochem Mol Biol; 2015 Feb; 146():26-37. PubMed ID: 24846829 [TBL] [Abstract][Full Text] [Related]
18. [Expression of ER alpha in chemically induced MDA-MB-435 cells and its responsiveness to endocrine]. Fan J; Lu JS; Yin WJ; Lei W; Wu FY; Wu J; Hou YF; Li DQ; Di GH; Shen ZZ; Shao ZM Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):886-9. PubMed ID: 17533736 [TBL] [Abstract][Full Text] [Related]
19. Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells. Jiang C; Guo J; Wang Z; Xiao B; Lee HJ; Lee EO; Kim SH; Lu J Breast Cancer Res; 2007; 9(6):R77. PubMed ID: 17986353 [TBL] [Abstract][Full Text] [Related]
20. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer. Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]